绝经后如何?WHAM研究:绝经前降低风险输卵管卵巢切除术后12个月血管舒缩症状与绝经相关生活质量的前瞻性对照研究
该前瞻性观察研究纳入95例计划行降低风险输卵管卵巢切除术(RRSO)的绝经前女性和99例保留卵巢的对照,测量基线、3、6、12个月的血管舒缩症状和绝经相关生活质量。RRSO后3个月潮热患病率从5.3%升至56.2%,夜汗从20.2%升至47.2%,3至12个月未加重,对照组无变化(p<0.001)。60%开始激素治疗,但40%激素治疗者仍有症状,80%未用激素者报告症状;86%症状为轻度。RRSO后生活质量下降,激素治疗者优于未用者,但未恢复至术前水平。
要点
- RRSO后3个月潮热和夜汗患病率显著增加,3至12个月未进一步加重。
- 60%启动激素治疗,但40%仍有血管舒缩症状,80%未用激素者报告症状。
- RRSO后生活质量下降,激素治疗可改善但未恢复至术前水平。
核心结论
- RRSO后3个月血管舒缩症状增加但12个月内不加重,激素治疗可减少症状并改善生活质量但未恢复至术前水平。
研究设计与样本
- 前瞻性观察研究,纳入95例计划行RRSO的绝经前女性和99例保留卵巢的对照。
- 在基线、3、6、12个月使用绝经特异性生活质量干预量表测量血管舒缩症状和绝经相关生活质量。
主要发现
- RRSO后3个月潮热患病率从5.3%升至56.2%,夜汗从20.2%升至47.2%,3至12个月无恶化,对照组无变化(p<0.001)。
- RRSO后60%开始激素治疗,但40%激素治疗者仍有血管舒缩症状,80%未用激素者报告症状。
- 无论是否使用激素治疗,86%的RRSO后血管舒缩症状被归类为「轻度」。
- RRSO后绝经相关生活质量恶化,对照组稳定(调整系数=0.75,95%CI=0.55-0.95)。
- RRSO后激素治疗者生活质量优于未用者(调整系数=0.49,95%CI=0.20-0.78)。
临床怎么用
- RRSO术前应告知患者术后3个月内血管舒缩症状可能显著增加,但12个月内不会持续加重。
- 激素治疗可减少血管舒缩症状并改善生活质量,但部分患者症状持续,需管理预期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To measure menopausal symptoms and quality of life up to 12 months after risk-reducing salpingo-oophorectomy (RRSO) and to measure the effects of hormone therapy. METHODS: Prospective observational study of 95 premenopausal women planning RRSO and a comparison group of 99 who retained their ovaries. Vasomotor symptoms and menopausal-related quality of life (QoL) were measured by the Menopause-Specific QoL Intervention scale at baseline, 3, 6 and 12 months. Chi-square tests measured differences in prevalence of vasomotor symptoms between RRSO vs the comparison group and by hormone therapy use. Change in QoL were examined with multilevel modelling. RESULTS: Three months after RRSO hot flush prevalence increased from 5.3% to 56.2% and night sweats from 20.2% to 47.2%. Symptoms did not worsen between 3 and 12 months and remained unchanged in the comparison group (p<0.001). After RRSO, 60% commenced hormone therapy. However, 40% of hormone therapy uses continued to experience vasomotor symptoms. After RRSO, 80% of non-hormone therapy users reported vasomotor symptoms. Regardless of hormone therapy use, 86% categorized their vasomotor symptoms as "mild" after RRSO. Following RRSO, Menopause-related QoL deteriorated but was stable in the comparison group (adjusted coefficient = 0.75, 95%CI = 0.55-0.95). After RRSO, QoL was better in hormone therapy users vs non-users (adjusted coefficient = 0.49, 95%CI = 0.20-0.78). CONCLUSIONS: Vasomotor symptoms increase by 3 months after RRSO but do not worsen over the next 12 months. Hormone Therapy reduces but does not resolve vasomotor symptoms and may improve QoL, but not to pre-oophorectomy levels.
引用
- Hickey M, Moss KM, Krejany EO, et al. What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy. Gynecol Oncol. 2021. PMID: 34312002. doi:10.1016/j.ygyno.2021.07.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。